Letermovir: First Global Approval. (Q49484467)

20 February 2018

review article

1 reference

title

Letermovir: First Global Approval. (English)

1 reference

20 February 2018

author name string

Esther S Kim

series ordinal

1

1 reference

20 February 2018

publication date

29 December 2017

1 reference

20 February 2018

published in

Drugs

1 reference

20 February 2018

volume

78

1 reference

20 February 2018

issue

1

1 reference

20 February 2018

page(s)

147-152

1 reference

20 February 2018

https://scigraph.springernature.com/pub.10.1007/s40265-017-0860-8

exact match

0 references

cites work

Cytomegalovirus in hematopoietic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0860-8

Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0860-8

The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0860-8

In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0860-8

Impact of glycoprotein B genotype and naturally occurring ORF UL56 polymorphisms upon susceptibility of clinical human cytomegalovirus isolates to letermovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0860-8

Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0860-8

Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0860-8

In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0860-8

Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0860-8

Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0860-8

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0860-8

Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-017-0860-8

First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29288370

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29288370

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40265-017-0860-8

1 reference

20 February 2018

Dimensions Publication ID

0 references

1 reference

20 February 2018